Hyperkalemia in heart failure: Why should we care?10' education - July 12, 2022 - Clara Bonanad Lozano, MD, PhD - Valencia, Spain
Video navigation menu
- Patient groups with a high incidence of hyperkalemia 00:33
- Therapeutic dilemma in managing hyperkalemia while optimizing RAASi therapy 01:20
- Reasons to optimize guideline directed medical therapy in HFrEF despite the risk of hyperkalemia 05:46
- Expert consensus document on managing hyperkalemia in patients with CVD and treated with RAASi. 07:39
- Conclusions 08:30
This lecture by Clara Bonanad Lozano was part of the EBAC-accredited symposium "Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalaemia" held during the ESC Heart Failure 2022 congress.
Clara Bonanad Lozano, MD, PhD is a Clinical Cardiologist at the University Clinical Hospital of Valencia, Spain and Associate Professor at the Department of Medicine of the University of Valencia, Spain.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.